A new chapter in CML treatment: the promise of asciminib
Open Access
- 28 February 2025
- journal article
- editorial
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1117-1119
Abstract
Asciminib, a groundbreaking treatment for chronic myeloid leukemia (CML), has gained FDA approval as the first STAMP inhibitor. Targeting the myristoyl pocket of the BCR-ABL1 protein, this drug offers a unique mechanism to overcome resistance to traditional tyrosine kinase inhibitors (TKIs). Clinical trials, such as the ASC4FIRST study, demonstrate asciminib’s superior efficacy compared to existing TKIs, achieving higher molecular response rates and fewer severe side effects. Its favorable safety profile, characterized by reduced vascular and pulmonary risks, supports improved patient adherence and long-term outcomes. While asciminib shows promise as a second-line or even frontline therapy, long-term data on its durability, adverse effects, and potential drug interactions are still evolving. Current research highlights its potential use in pediatric cases and in combination therapies for other leukemia types. Asciminib represents a significant advancement in CML treatment, paving the way for more targeted and tolerable cancer therapies.Keywords
This publication has 9 references indexed in Scilit:
- Clinical Pharmacology of Asciminib: A ReviewClinical Pharmacokinetics, 2024
- Asciminib in Advanced‐Line Treatment of Chronic Myeloid LeukemiaEuropean Journal of Haematology, 2024
- Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2024
- Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cellsLeukemia, 2024
- Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case ReportCase Reports in Oncology, 2024
- S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.HemaSphere, 2023
- Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase InhibitorsCancers, 2023
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureNew England Journal of Medicine, 2019
- Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemiaNature Reviews Cancer, 2005